ReviveRX
ReviveRX is a licensed 503A mail-order compounding pharmacy that prepares commercially available and custom-compounded medications for healthcare providers and their patients.
Classification
Profile
Not yet available.
Funding
Funding details not yet available.
Compliance
Fundraising & market
Provides customizable, USP-compliant compounded medications and dependable fulfillment to support healthcare providers' patient care needs.
Healthcare providers, physicians, and clinicians in the DACH region who prescribe specialized medications.
Charges for the preparation and dispensing of custom-compounded medications and commercial products.
Direct partnership with healthcare providers; ships medications directly to patients via mail-order.
Healthcare providers who prescribe their medications; acts as a nationwide compounding pharmacy partner.
Costs driven by licensed clean room operations, pharmaceutical ingredient sourcing, regulatory compliance, and logistics.
USP-compliant clean rooms, 503A licensure, specialized pharmacists, and a nationwide distribution network.
Preparing custom-compounded medications, ensuring USP compliance, managing inventory, and shipping to patients.
Partnership approach with healthcare providers; focuses on consistent service and dependable turnaround times.
Competes with other mail-order compounding pharmacies; differentiates through nationwide availability and provider-focused service.
Lack of access to custom formulations, inconsistent supply of specialized drugs, and need for reliable patient fulfillment.
- Strengthen QA & Transparency
Risk Mitigation - Investing in compliance now prevents costly shutdowns and protects brand equity, directly influencing the Cost Structure a · Differentiation - By turning QA transparency into a marketable feature, ReviveRX can command higher margins and defend against low-cost gene · Scalability - Streamlined digital onboarding and logistics partn
- Regulatory Red Flag - The September 2025 FDA warning letter indicates serious compliance gaps; investors and partners will scrutinize QA
Team details not yet available.
No investors recorded yet.